{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T02:10:04Z","timestamp":1744251004005,"version":"3.40.4"},"publisher-location":"Vienna","reference-count":77,"publisher":"Springer Vienna","isbn-type":[{"type":"print","value":"9783211832752"},{"type":"electronic","value":"9783709163603"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999]]},"DOI":"10.1007\/978-3-7091-6360-3_4","type":"book-chapter","created":{"date-parts":[[2012,10,6]],"date-time":"2012-10-06T01:06:34Z","timestamp":1349485594000},"page":"83-105","source":"Crossref","is-referenced-by-count":9,"title":["Multiple mechanisms of action: the pharmacological profile of budipine"],"prefix":"10.1007","author":[{"given":"M.","family":"Eltze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"4_CR1","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","volume":"12","author":"RL Albin","year":"1989","unstructured":"Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurol Sci 12: 366\u2013375","journal-title":"Trends Neurol Sci"},{"key":"4_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1212\/WNL.35.7.949","volume":"35","author":"P Ballard","year":"1985","unstructured":"Ballard P, Tetrud JW, Langston W (1985) Permanent human parkinsonism due to l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Seven cases. Neurology 35: 949\u2013959","journal-title":"Neurology"},{"key":"4_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1126\/science.2402638","volume":"249","author":"H Bergman","year":"1990","unstructured":"Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249: 1436\u20131438","journal-title":"Science"},{"key":"4_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/978-3-642-95455-9_24","volume-title":"Clinical experiences with budipine in Parkinson therapy","author":"S Bien","year":"1985","unstructured":"Bien S, W\u00f6rz R (1985) Budipine-treatment of neuroleptic-induced parkinsonism. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 169\u2013175"},{"key":"4_CR5","first-page":"1242","volume":"30","author":"U Brand","year":"1980","unstructured":"Brand U, Menge HG (1980) Antagonismus gegen den Tremor nach N-Carbamoyl-2-(2,6-dichlorphenyl)-acetamidin HCl (LON-954) und Oxotremorin. Eine vergleichende Studie zum Wirkungsmechanismus. Arzneim Forsch\/Drug Res 30: 1242\u20131243","journal-title":"Arzneim Forsch\/Drug Res"},{"key":"4_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/mds.870060208","volume":"6","author":"JM Brotchie","year":"1991","unstructured":"Brotchie JM, Mitchell IJ, Sambrook MA, Crossman AR (1991) Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov Disord 6: 133\u2013138","journal-title":"Mov Disord"},{"key":"4_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0028-3908(94)00138-I","volume":"34","author":"RE Brown","year":"1995","unstructured":"Brown RE, Fedorov NB, Haas HL, Reymann KG (1995) Histaminergic modulation of synaptic plasticity in area CA1 of rat hippocampal slices. Neuropharmacology 34: 181\u2013190","journal-title":"Neuropharmacology"},{"key":"4_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1126\/science.847477","volume":"196","author":"DR Burt","year":"1977","unstructured":"Burt DR, Creese J, Snyder SH (1977) Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196: 326\u2013328","journal-title":"Science"},{"key":"4_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/0166-2236(90)90108-M","volume":"13","author":"M Carlsson","year":"1990","unstructured":"Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia \u2014 implications for schizophrenia and Parkinson\u2019s disease. Trends Neurosci 13: 272\u2013276","journal-title":"Trends Neurosci"},{"key":"4_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/0028-3908(77)90004-1","volume":"16","author":"DM Coward","year":"1977","unstructured":"Coward DM, Dogget NS, Thomas JE (1977) Central transmitter involvement in LON-954-induced tremorgenesis. Neuropharmacology 16: 479\u2013484","journal-title":"Neuropharmacology"},{"key":"4_CR11","first-page":"157","volume":"18","author":"G Debonnel","year":"1995","unstructured":"Debonnel G (1995) Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry. J Psychiatr Neurosci 18: 157\u2013172","journal-title":"J Psychiatr Neurosci"},{"key":"4_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00002512-199609030-00002","volume":"9","author":"R Paola Di","year":"1996","unstructured":"Di Paola R, Utti RJ (1996) Early detection of Parkinson\u2019s disease. Implications for treatment. Drugs Aging 9: 159\u2013168","journal-title":"Drugs Aging"},{"key":"4_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0301-0082(95)00029-1","volume":"48","author":"M Ebadi","year":"1996","unstructured":"Ebadi M, Srinivasan SK, Baxi MD (1996) Oxidative stress and antioxidant therapy in Parkinson\u2019s disease. Progr Neurobiol 48: 1\u201319","journal-title":"Progr Neurobiol"},{"key":"4_CR14","first-page":"1129","volume":"30","author":"M Eltze","year":"1980","unstructured":"Eltze M (1980) The effects of prodipine and budipine on [14C]5-HT uptake and release by human blood platelets. Arzneim Forsch\/Drug Res 30: 1129\u20131134","journal-title":"Arzneim Forsch\/Drug Res"},{"key":"4_CR15","doi-asserted-by":"publisher","first-page":"239P","DOI":"10.1038\/sj.bjp.0700915","volume":"120","author":"A Fisher","year":"1997","unstructured":"Fisher A, Biggs CS, Starr MS (1997) Evidence that glutamate regulates dopamine synthesis via aromatic L-amino acid decarboxylase. Br J Pharmacol 120 [Suppl]: 239P","journal-title":"Br J Pharmacol"},{"key":"4_CR16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1515\/znb-1983-0221","volume":"38b","author":"M Gerlach","year":"1983","unstructured":"Gerlach M, Jutzi P, Stasch JP, Przuntek H (1983) Synthese und pharmakologische Eigenschaften von silierten Dopaminen und 4,4-Diphenylpiperidinen. Z Naturforsch 38b: 237\u2013242","journal-title":"Z Naturforsch"},{"key":"4_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0014-2999(90)90224-T","volume":"175","author":"MT Giralt","year":"1990","unstructured":"Giralt MT, Bonnano G, Raiteri M (1990) GABA terminal autoreceptors in the pars compacta and in the pars reticulata of substantia nigra are GABA B. Eur J Pharmacol 175: 137\u2013144","journal-title":"Eur J Pharmacol"},{"key":"4_CR18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/archneur.1991.00530210109030","volume":"48","author":"JT Greenamyre","year":"1991","unstructured":"Greenamyre JT, O\u2019Brian CF (1991) N-methyl-D-aspartate antagonists in the treatment of Parkinson\u2019s disease. Arch Neurol 48: 977\u2013981","journal-title":"Arch Neurol"},{"key":"4_CR19","first-page":"61","volume":"80","author":"G Hackmack","year":"1979","unstructured":"Hackmack G, Menge HG, Eistetter K, Kr\u00fcger U, Schaefer H, Klosa J (1979) 4,4-Diphenylpiperidine, ein neuer Substanztyp f\u00fcr die Therapie des Morbus Parkinson. \u00d6sterr Chem Ztschr 80: 61\u201362","journal-title":"\u00d6sterr Chem Ztschr"},{"key":"4_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0922-4106(95)90173-6","volume":"289","author":"M Hadjiconstantinou","year":"1995","unstructured":"Hadjiconstantinou M, Rosetti ZL, Wemlinger TA, Neff NH (1995) Dizozilpine enhances striatal tyrosine hydroxylase and aromatic L-amino acid decarboxylase activity. Eur J Pharmacol 289: 97\u2013101","journal-title":"Eur J Pharmacol"},{"key":"4_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/BF00499253","volume":"315","author":"G Hertting","year":"1980","unstructured":"Hertting G, Zumstein A, Jackisch R, Hoffmann I, Starke K (1980) Modulation by endogenous dopamine of the release of acetylcholine in the caudate nucleus of the rabbit. Naunyn-Schmiedeb Arch Pharmacol 315: 111\u2013117","journal-title":"Naunyn-Schmiedeb Arch Pharmacol"},{"key":"4_CR22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0031-6997(25)07154-6","volume":"18","author":"O Hornykiewicz","year":"1966","unstructured":"Hornykiewicz O (1966) Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 18: 925\u2013964","journal-title":"Pharmacol Rev"},{"key":"4_CR23","first-page":"184","volume":"57","author":"J Iizuka","year":"1986","unstructured":"Iizuka J, Fischer R (1986) Beeinflussung des Parkinson-Tremors durch Budipin: Eine Vergleichsstudie mit Amantadin. Nervenarzt 57: 184\u2013186","journal-title":"Nervenarzt"},{"key":"4_CR24","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0022-3565(25)10222-X","volume":"264","author":"R Jackisch","year":"1993","unstructured":"Jackisch R, Huang HY, Reimann W, Limberger N (1993) Effects of the antiparkinsonian drug budipine on neurotransmitter release in central nervous system tissues in vitro. J Pharmacol Exp Ther 264: 889\u2013898","journal-title":"J Pharmacol Exp Ther"},{"key":"4_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0014-2999(94)00528-1","volume":"264","author":"R Jackisch","year":"1994","unstructured":"Jackisch R, Kruchen A, Sauermann W, Hertting G, Feuerstein TJ (1994) The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists. Eur J Pharmacol 264: 207\u2013211","journal-title":"Eur J Pharmacol"},{"key":"4_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/BF00314280","volume":"234","author":"K Jellinger","year":"1987","unstructured":"Jellinger K, Bliesath H (1987) Adjuvant treatment of Parkinson\u2019s disease with budipine: A double-blind trial versus placebo. J Neurol 234: 280\u2013282","journal-title":"J Neurol"},{"key":"4_CR27","first-page":"R23","volume":"357","author":"C Keim","year":"1998","unstructured":"Keim C, Mutschier E, Lambrecht G, Eltze M (1998) Affinity of the antiparkinsonian drug, budipine, on native muscarinic M1-M3 and human recombinant ml-m5 receptors. Naunyn-Schmiedeb Arch Pharmacol 357 [Suppl]: R23","journal-title":"Naunyn-Schmiedeb Arch Pharmacol"},{"key":"4_CR28","first-page":"314","volume-title":"Schizophrenia \u2014 an integrated view. Alfred Benzon Symposium 38","author":"J Kornhuber","year":"1995","unstructured":"Kornhuber J, Weller M (1995) Predicting psychotomimetic properties of PCP-like NMDA receptor antagonists. In: Fog R, Gerlach J, Hemmingsen R, Krogsgaard-Larsen P, Thaysen JH (eds) Schizophrenia \u2014 an integrated view. Alfred Benzon Symposium 38. Munksgaard, Copenhagen, pp 314\u2013325"},{"key":"4_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0006-3223(96)00047-9","volume":"41","author":"J Kornhuber","year":"1997","unstructured":"Kornhuber J, Weller M (1997) Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy. Biol Psychiatry 41: 135\u2013144","journal-title":"Biol Psychiatry"},{"key":"4_CR30","first-page":"91","volume":"43","author":"J Kornhuber","year":"1994","unstructured":"Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm [Suppl] 43: 91\u2013104","journal-title":"J Neural Transm [Suppl]"},{"key":"4_CR31","first-page":"131","volume":"46","author":"J Kornhuber","year":"1995","unstructured":"Kornhuber J, Herr B, Thome J, Riederer P (1995) The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue. J Neural Transm [Suppl] 46: 131\u2013137","journal-title":"J Neural Transm [Suppl]"},{"key":"4_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0166-2236(89)90007-6","volume":"12","author":"T Klockgether","year":"1989","unstructured":"Klockgether T, Turski L (1989) Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson\u2019s disease. Trends Neurosci 12: 285\u2013286","journal-title":"Trends Neurosci"},{"key":"4_CR33","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/ana.410340413","volume":"34","author":"T Klockgether","year":"1993","unstructured":"Klockgether T, Turski L (1993) Towards the understanding of the role of glutamate in experimental parkinsonism: agonist-sensive sites in the basal ganglia. Ann Neurol 34: 585\u2013593","journal-title":"Ann Neurol"},{"key":"4_CR34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF02251200","volume":"5","author":"T Klockgether","year":"1993","unstructured":"Klockgether T, Jacobsen P, L\u00f6schmann PA, Turski L (1993) The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J Neural Transm [P D Sect] 5: 101\u2013106","journal-title":"J Neural Transm [P D Sect]"},{"key":"4_CR35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0014-2999(96)00046-5","volume":"301","author":"T Klockgether","year":"1996","unstructured":"Klockgether T, W\u00fcllner U, Steinbach JP, Petersen V, Turski L, L\u00f6schmann PA (1996) Effect of the antiparkinsonian drug budipine on central neurotransmitter systems. Eur J Pharmacol 301: 67\u201373","journal-title":"Eur J Pharmacol"},{"key":"4_CR36","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1526-4610.1988.hed2805344.x","volume":"28","author":"H Kr\u00fcger","year":"1988","unstructured":"Kr\u00fcger H, Kohlhepp W, Reimann G, Przuntek H (1988) Prophylactic treatment of cluster headache with budipine. Headache 28: 344\u2013346","journal-title":"Headache"},{"key":"4_CR37","first-page":"S527","volume":"22","author":"W Kuhn","year":"1987","unstructured":"Kuhn W, Russ H, Dettner O, Gerlach M, Przuntek H (1987) Interaction of deprenyl and budipine with MAO-B in vivo and in vitro. Neuroscience 22 [Suppl]: S527","journal-title":"Neuroscience"},{"key":"4_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/BF02259538","volume":"3","author":"PA L\u00f6schmann","year":"1991","unstructured":"L\u00f6schmann PA, Lange KW, Kunow M, Rettig KJ, J\u00e4hnig P, Honore T, Turski L, Wachtel H, Jenner P, Marsden CD (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-DOPA in models of Parkinson\u2019s disease. J Neural Transm [P D Sect] 3: 203\u2013207","journal-title":"J Neural Transm [P D Sect]"},{"key":"4_CR39","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0022-3565(25)10406-0","volume":"263","author":"A Lupp","year":"1992","unstructured":"Lupp A, L\u00fccking CH, Koch R, Jackisch R, Feuerstein TJ (1992) Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus. J Pharmacol Exp Ther 263: 717\u2013724","journal-title":"J Pharmacol Exp Ther"},{"key":"4_CR40","first-page":"R108","volume":"353","author":"A Lupp","year":"1996","unstructured":"Lupp A, Karge E, Klinger W (1996) Antioxidant properties of NMDA-receptor agonists and antagonists on the microsomal cytochrome P-450 system of rat livers in vitro. Naunyn-Schmiedb Arch Pharmacol 353 [Suppl]: R108","journal-title":"Naunyn-Schmiedb Arch Pharmacol"},{"key":"4_CR41","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2466\/pr0.1994.74.3.723","volume":"74","author":"CJ McBain","year":"1994","unstructured":"McBain CJ, Mayer ML (1994) N-methyl-D-aspartatic acid receptor structure and function. Physiol Rev 74: 723\u2013760","journal-title":"Physiol Rev"},{"key":"4_CR42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/978-3-642-95455-9_13","volume-title":"Clinical experiences with budipine in Parkinson therapy","author":"HG Menge","year":"1985","unstructured":"Menge HG, Brand U (1985) Pharmacologic bases of antiparkinsonian therapy. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 82\u201392"},{"key":"4_CR43","first-page":"85","volume":"32","author":"HG Menge","year":"1982","unstructured":"Menge HG, Brand U, Dittmann EC, Eltze M, Gernandt W, G\u00f6nne S, M\u00fcller H, Steinijans V (1982) Zusammenfassende Darstellung der Pharmakologie von Budipin, einem neuen 4,4-Diphenylpiperidin-Derivat f\u00fcr die Parkinson-Therapie. Arzneim Forsch\/Drug Res 32: 85\u201398","journal-title":"Arzneim Forsch\/Drug Res"},{"key":"4_CR44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/BF01245711","volume":"71","author":"W Mihatsch","year":"1988","unstructured":"Mihatsch W, Russ H, Przuntek H (1988) Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: effects of simultaneously administered nomifensine, deprenyl and 1-t-butyl-4,4-diphenylpiperidine. J Neural Transm 71: 177\u2013188","journal-title":"J Neural Transm"},{"key":"4_CR45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0022-3565(25)10951-8","volume":"261","author":"FP Monnet","year":"1992","unstructured":"Monnet FP, Debonnel G, DeMontigny C (1992) In vivo electrophysiological evidence for a selective modulation of N-methyl-D-aspartate-induced neuronal activation in rat CA3 dorsal hippocampus by sigma ligands. J Pharmacol Exp Ther 261: 123\u2013130","journal-title":"J Pharmacol Exp Ther"},{"key":"4_CR46","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0014-2999(83)90344-8","volume":"87","author":"D Neuser","year":"1983","unstructured":"Neuser D, Stasch JP, Witteler M, Kuhn W, Gerlach M, Jutzi P, Przuntek H (1983) The interaction of 1-alkyl-4,4-diphenylpiperidines with opiate receptors. Eur J Pharmacol 87: 315\u2013318","journal-title":"Eur J Pharmacol"},{"key":"4_CR47","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/0003-9861(90)90741-G","volume":"276","author":"HB Niznik","year":"1990","unstructured":"Niznik HB, Tyndale RF, Sallee FR, Gonzales FJ, Hardwick JP, Inaba T, Kalow W (1990) The dopamine transporter and cytochrome P-450 IID1 (debrisoquine-4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. Arch Biochem Biophys 276: 424\u2013432","journal-title":"Arch Biochem Biophys"},{"key":"4_CR48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-3-642-95455-9_14","volume-title":"Clinical experiences with budipine in Parkinson therapy","author":"J Offermeier","year":"1985","unstructured":"Offermeier J, van Rooyen JM (1985) The pharmacodynamics of budipine on central neurotransmitter systems. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 93\u2013105"},{"key":"4_CR49","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/978-3-642-95455-9_23","volume-title":"Clinical experiences with budipine in Parkinson therapy","author":"F Oppel","year":"1985","unstructured":"Oppel F (1985) Long-term treatment with budipine. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 163\u2013168"},{"key":"4_CR50","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/0028-3908(95)00092-K","volume":"34","author":"CG Parsons","year":"1995","unstructured":"Parsons CG, Quack G, Bresink I, Baran L. Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34: 1239\u20131258","journal-title":"Neuropharmacology"},{"key":"4_CR51","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0028-3908(98)00059-8","volume":"37","author":"CG Parsons","year":"1998","unstructured":"Parsons CG, Hartmann S, Spielmanns P (1998) Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist: patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones. Neuropharmacology 37: 719\u2013727","journal-title":"Neuropharmacology"},{"key":"4_CR52","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0701123","volume":"121","author":"GW Payne","year":"1997","unstructured":"Payne GW, Neuman RS (1997) Effect of hypomagnesia on histamine H1 receptor mediated facilitation of NMDA responses. Br J Pharmacol 121: 199\u2013204","journal-title":"Br J Pharmacol"},{"key":"4_CR53","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/j.1471-4159.1983.tb08102.x","volume":"40","author":"TL Perry","year":"1983","unstructured":"Perry TL, Javoy-Agid F, Fibiger HC (1983) Striatal GABAergic neuronal activity is not reduced in Parkinson\u2019s disease. J Neurochem 40: 1120\u20131123","journal-title":"J Neurochem"},{"key":"4_CR54","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/978-3-642-95455-9_17","volume-title":"Clinical experiences with budipine in Parkinson therapy","author":"W Poewe","year":"1985","unstructured":"Poewe W, Gerstenbrand F, Ransmayr G (1985) Clinical experience with budipine in parkinsonian therapy. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 122\u2013128"},{"key":"4_CR55","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1046\/j.1471-4159.1995.64020614.x","volume":"64","author":"RHP Porter","year":"1995","unstructured":"Porter RHP, Greenamyre JT (1995) Regional variation in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 64: 614\u2013623","journal-title":"J Neurochem"},{"key":"4_CR56","first-page":"309","volume":"34","author":"E Przegalinski","year":"1982","unstructured":"Przegalinski E, Bigajska K, Lewandowska A (1982) The effect of budipine on the central serotonergic system. Pol J Pharmacol Pharm 34: 309\u2013315","journal-title":"Pol J Pharmacol Pharm"},{"key":"4_CR57","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-3-642-95455-9_15","volume-title":"Clinical experiences with budipine in Parkinson therapy","author":"H Przuntek","year":"1985","unstructured":"Przuntek H, Stasch JP (1985) Biochemical and pharmacologic aspects of the mechanism of action of budipine. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 107\u2013112"},{"key":"4_CR58","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/0024-3205(85)90130-4","volume":"37","author":"H Przuntek","year":"1985","unstructured":"Przuntek H, Russ H, Henning K, Pindur U (1985) The protective effect of 1-t-butyl-4,4-diphenylpiperidine against the nigrostriatal neurodegeneration caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 37: 1195\u20131200","journal-title":"Life Sci"},{"key":"4_CR59","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0165-6147(92)90030-A","volume":"13","author":"R Quirion","year":"1992","unstructured":"Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, Rothmann RB, Su TP, Tam SW, Taylor DP (1992) A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 13: 85\u201386","journal-title":"Trends Pharmacol Sci"},{"key":"4_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF00515593","volume":"306","author":"W Reimann","year":"1979","unstructured":"Reimann W, Zumstein A, Jackisch R, Starke K, Hertting G (1979) Effect of extracellular dopamine on the release of dopamine in the rabbit caudate nucleus: evidence for a dopaminergic feedback inhibition. Naunyn-Schmideb Arch Pharmacol 306: 53\u201360","journal-title":"Naunyn-Schmideb Arch Pharmacol"},{"key":"4_CR61","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0304-3940(85)90141-7","volume":"59","author":"GA Ricaurte","year":"1985","unstructured":"Ricaurte GA, Langston JW, DeLanney LE, Irwin I, Brooks JP (1985) Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci Lett 59: 265\u2013270","journal-title":"Neurosci Lett"},{"key":"4_CR62","first-page":"757","volume-title":"Verhandlungen der Deutschen Gesellschaft f\u00fcr","author":"H Russ","year":"1983","unstructured":"Russ H, Stasch JP, Witteler M, Neuser D, Przuntek (1983) Der Effekt von Budipin auf das Parkinson Syndrom. Versuch einer neuropharmakologischen Erkl\u00e4rung. In: Seitz D (ed) Verhandlungen der Deutschen Gesellschaft f\u00fcr Neurologic Springer, Berlin Heidelberg New York Tokyo, pp 757\u2013760"},{"key":"4_CR63","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/BF01249078","volume":"65","author":"H Russ","year":"1986","unstructured":"Russ H, Pindur U, Przuntek H (1986) The interaction of 1-alkyl-4,4-diphenylpiperidines with the 1-methyl-1,2,3,6-tetrahydropyridine receptor binding site. J Neural Transm 65: 157\u2013165","journal-title":"J Neural Transm"},{"key":"4_CR64","first-page":"233","volume":"34","author":"H Schaefer","year":"1984","unstructured":"Schaefer H, Hackmack K, Eistetter K, Kr\u00fcger U, Menge HG, Klosa J (1984) Synthese, physikalis ch-chemische Eigenschaften und orientierende pharmakologische Untersuchungen von Budipin und verwandten 4,4-Diphenylpiperidinen. Arzneim Forsch\/Drug Res 34: 233\u2013240","journal-title":"Arzneim Forsch\/Drug Res"},{"key":"4_CR65","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/0091-3057(89)90007-5","volume":"32","author":"WJ Schmidt","year":"1989","unstructured":"Schmidt WJ, Bubser M (1989) Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 32: 621\u2013629","journal-title":"Pharmacol Biochem Behav"},{"key":"4_CR66","first-page":"1977","volume":"41","author":"J Siegfried","year":"1983","unstructured":"Siegfried J, Fischer R (1983) La place pour une nouvelle substance chimique dans le traitment de la maladie de Parkinson et la role de la budipine. Med et Hyg 41: 1977\u20131981","journal-title":"Med et Hyg"},{"key":"4_CR67","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/978-3-642-95455-9_21","volume-title":"Clinical experiences with budipine in Parkinson therapy","author":"J Siegfried","year":"1985","unstructured":"Siegfried J, Fischer R (1985) Budipine: A new chemical substance in the treatment of Parkinson\u2019s disease. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 152\u2013157"},{"key":"4_CR68","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0014-2999(96)00782-0","volume":"318","author":"LE Soria-Jasso","year":"1996","unstructured":"Soria-Jasso LE, Arias-Montano JA (1996) Histamine H1 receptor activation stimulates [3H]GABA release from human astrocytoma U373 MG cells. Eur J Pharmacol 318: 185\u2013192","journal-title":"Eur J Pharmacol"},{"key":"4_CR69","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/00002826-199506000-00007","volume":"18","author":"S Spieker","year":"1995","unstructured":"Spieker S, L\u00f6schmann P, Jentgens C, Boose A, Klockgether T, Dichgans (1995) Tremorlytic activity of budipine. a quantitative study with long-term tremor recordings. Clin Neuropharmacol 18: 266\u2013272","journal-title":"Clin Neuropharmacol"},{"key":"4_CR70","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/BF02251229","volume":"10","author":"MS Starr","year":"1995","unstructured":"Starr MS (1995) Antiparkinsonian actions of glutamate antagonists \u2014 alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms. J Neural Transm [P D Sect] 10: 141\u2013185","journal-title":"J Neural Transm [P D Sect]"},{"key":"4_CR71","first-page":"55","volume":"15","author":"MS Starr","year":"1997","unstructured":"Starr MS, Fisher A, Biggs CS (1997) Effect of glutamate antagonists on dopamine synthesis. Amino Acids 15: 55","journal-title":"Amino Acids"},{"key":"4_CR72","first-page":"1075","volume":"38","author":"JP Stasch","year":"1988","unstructured":"Stasch JP, Ru\u00df H, Schacht M, Witteler M, Neuser D, Gerlach M, Leven M, Kuhn W, Jutzi P, Przuntek H (1988) 4,4-Diphenylpiperidine derivatives and their sila analogues. A comparative study of their interaction with neuronal receptor binding sites and synaptosomal monoamine uptake. Arzneim Forsch\/Drug Res 38: 1075\u20131078","journal-title":"Arzneim Forsch\/Drug Res"},{"key":"4_CR73","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/0304-3940(90)90496-V","volume":"113","author":"L Turski","year":"1990","unstructured":"Turski L, Bressler K, Klockgether T, Stephens DN (1990) Differential effects of the excitatory amino acid antagonists, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 3-(\u00b1)-2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP), on spinal reflex activity in mice. Neurosci Lett 113: 66\u201371","journal-title":"Neurosci Lett"},{"key":"4_CR74","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0031-6997(25)00047-X","volume":"42","author":"JM Walker","year":"1990","unstructured":"Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC (1990) Sigma receptors: biology and function. Pharmacol Rev 42: 355\u2013402","journal-title":"Pharmacol Rev"},{"key":"4_CR75","first-page":"158","volume-title":"Clinical experiences with budipine in Parkinson therapy","author":"Y Wang","year":"1985","unstructured":"Wang Y (1985) Observations on the therapeutic effect of budipine on Parkinson\u2019s disease. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 158\u2013162"},{"key":"4_CR76","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/978-3-642-95455-9_16","volume-title":"Clinical experiences with budipine in Parkinson therapy","author":"K Zech","year":"1985","unstructured":"Zech K, Sturm E, Ludwig G (1985) Pharmacokinetics and metabolism of budipine in animals and humans. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 113\u2013121"},{"key":"4_CR77","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/j.1471-4159.1992.tb09765.x","volume":"58","author":"MY Zhu","year":"1992","unstructured":"Zhu MY, Juorio AV, Paterson IA, Boulton AA (1992) Regulation of aromatic L-amino acid decarboxylase by dopamine receptors in rat brain. J Neurochem 58: 636\u2013641","journal-title":"J Neurochem"}],"container-title":["Journal of Neural Transmission. Supplementa","Diagnosis and Treatment of Parkinson\u2019s Disease \u2014 State of the Art"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-7091-6360-3_4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T01:30:21Z","timestamp":1744248621000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-7091-6360-3_4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999]]},"ISBN":["9783211832752","9783709163603"],"references-count":77,"URL":"https:\/\/doi.org\/10.1007\/978-3-7091-6360-3_4","relation":{},"ISSN":["0303-6995"],"issn-type":[{"type":"print","value":"0303-6995"}],"subject":[],"published":{"date-parts":[[1999]]}}}